Trial Profile
A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-Based Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ICEBERG-3
- Sponsors AstraZeneca
- 02 Oct 2018 Status changed from active, no longer recruiting to completed.
- 29 Nov 2017 Planned End Date changed from 29 Dec 2017 to 28 Dec 2018.
- 27 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.